Stent Companies Begin Post-Meeting Spin
In the aftermath of a CDRH panel meeting that raised concerns about the safety of drug-eluting stents in high-risk patients, Johnson & Johnson and Boston Scientific have launched aggressive campaigns to raise awareness of doctors and patients, reports the Boston Globe. J&J has conducted a number of conference calls with doctors about stent safety, and Boston Scientific has put out a bunch of new information in print ads and on its Web site.
December 12, 2006
1 Min Read
They are emphasizing the panel's conclusion that drug-eluting stents are safe and effective when used as approved, and that drug-eluting stent patients are not more likely than bare-metal stent patients to have heart attacks or die.
Sign up for the QMED & MD+DI Daily newsletter.
You May Also Like